Search

Author/Creator Delyon, J.

3. Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy. (12th November 2020)

Authors:
Haddad, N.; Delyon, J.; Trabelsi Messai, S.; Herms, F.; Leccia, M.T.; Lebbe, C.; Whitney, J.; Bhatia, S.; Basset‐Seguin, N.
Journal:
British journal of dermatology
Issue:
Volume 184:Number 3(2021)
Page Start:
564
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy. (1st March 2021)

Authors:
Haddad, N.; Delyon, J.; Trabelsi Messai, S.; Herms, F.; Leccia, M.T.; Lebbe, C.; Whitney, J.; Bhatia, S.; Basset‐Seguin, N.
Journal:
British journal of dermatology
Issue:
Volume 184:Number 3(2021)
Page Start:
564
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas. (1st December 2019)

Authors:
Dumont, M.; Ram‐Wolff, C.; Roelens, M.; Brice, P.; Peffault de Latour, R.; Battistella, M.; Madelaine, I.; Delyon, J.; Herms, F.; Bouaziz, J.‐D.; Moins‐Teisserenc, H.; Lebbé, C.; Bagot, M.; de Masson, A.
Journal:
British journal of dermatology
Issue:
Volume 181:Number 6(2019)
Page Start:
1315
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Efficacy and safety of brentuximab vedotin plus bendamustine in advanced‐stage primary cutaneous T‐cell lymphomas. (22nd August 2019)

Authors:
Dumont, M.; Ram‐Wolff, C.; Roelens, M.; Brice, P.; Peffault de Latour, R.; Battistella, M.; Madelaine, I.; Delyon, J.; Herms, F.; Bouaziz, J.‐D.; Moins‐Teisserenc, H.; Lebbé, C.; Bagot, M.; de Masson, A.
Journal:
British journal of dermatology
Issue:
Volume 181:Number 6(2019)
Page Start:
1315
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. (May 2021)

Authors:
Ghisoni, E.; Wicky, A.; Bouchaab, H.; Imbimbo, M.; Delyon, J.; Gautron Moura, B.; Gérard, C.L.; Latifyan, S.; Özdemir, B.C.; Caikovski, M.; Pradervand, S.; Tavazzi, E.; Gatta, R.; Marandino, L.; Valabrega, G.; Aglietta, M.; Obeid, M.; Homicsko, K.; Mederos Alfonso, N.N.; Zimmermann, S.
Journal:
European journal of cancer
Issue:
Volume 149(2021)
Page Start:
153
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Malignant, benign conventional and regulatory T immune compartments in 36 patients treated with mogamulizumab for advanced CTCL. (2019)

Authors:
Roelens, M.; de Masson, A.; Battistella, M.; Mourah, S.; Estevez, M.J.; Delyon, J.; Herms, F.; Ram-Wolff, C.; Lebbé, C.; Bagot, M.; Moins-Teisserenc, H.
Journal:
European journal of cancer
Issue:
Volume 119(2019)Supplement 1
Page Start:
S4
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗